These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492 [TBL] [Abstract][Full Text] [Related]
9. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182 [TBL] [Abstract][Full Text] [Related]
10. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis]. Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417 [TBL] [Abstract][Full Text] [Related]
11. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. Chan JG; Tyne AS; Pang A; McLachlan AJ; Perera V; Chan JC; Britton WJ; Chan HK; Duke CC; Young PM; Traini D Int J Antimicrob Agents; 2015 Mar; 45(3):319-23. PubMed ID: 25554469 [TBL] [Abstract][Full Text] [Related]
12. Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse? Wallis RS Am J Respir Crit Care Med; 2005 Jul; 172(1):4-5. PubMed ID: 15980108 [No Abstract] [Full Text] [Related]
13. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. Bemer-Melchior P; Bryskier A; Drugeon HB J Antimicrob Chemother; 2000 Oct; 46(4):571-6. PubMed ID: 11020254 [TBL] [Abstract][Full Text] [Related]
15. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107 [TBL] [Abstract][Full Text] [Related]
16. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Rastogi N; Goh KS; Berchel M; Bryskier A J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. Kaushik A; Ammerman NC; Tasneen R; Story-Roller E; Dooley KE; Dorman SE; Nuermberger EL; Lamichhane G J Antimicrob Chemother; 2017 Aug; 72(8):2320-2325. PubMed ID: 28575382 [TBL] [Abstract][Full Text] [Related]
18. Rifapentine: its role in the treatment of tuberculosis. Temple ME; Nahata MC Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321 [TBL] [Abstract][Full Text] [Related]
19. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis. Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874 [TBL] [Abstract][Full Text] [Related]
20. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]